The drug targets a specific mutation that applies to only 2% of ALS patients.
“[…]we have identified FGF21 as a novel biomarker in ALS that is detected in multiple compartments including muscle, spinal cord, and circulation.” In this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback